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Abstract
Background:Utilization of stereotactic radiosurgery (SRS) for treatment of high-grade gliomas (HGGs) has been slowly increasing
with variable reported success rates.
Objective: Systematic review of the available data to evaluate the efficacy of SRS as a treatment for HGG with regards to median
overall survival (OS) and progression-free survival (PFS), in addition to ascertaining the rate of radiation necrosis and other SRS-
related major neurological complications.
Methods: Literature searches were performed for publications from 1992 to 2016. The pooled estimates of median PFS and
median OS were calculated as a weighted estimate of population medians. Meta-analyses of published rates of radiation necrosis
and other major neurological complications were also performed.
Results: Twenty-nine studies reported the use of SRS for recurrent HGG, and 16 studies reported the use of SRS for newly
diagnosed HGG. For recurrent HGG, the pooled estimates of median PFS and median OS were 5.42 months (3–16 months) and
20.19 months (9–65 months), respectively; the pooled radiation necrosis rate was 5.9% (0–44%); and the pooled estimates of major
neurological complications rate was 3.3% (0–23%). For newly diagnosed HGG, the pooled estimates of median PFS and median OS
were 7.89months (5.5–11months) and 16.87months (9.5–33months) respectively; the pooled radiation necrosis rate was 6.5% (0–
33%); and the pooled estimates of other major neurological complications rate was 1.5% (0–25%).
Conclusion:Our results suggest that SRS holds promise as a relatively safe treatment option for HGG. In terms of efficacy at this
time, there are inadequate data to support routine utilization of SRS as the standard of care for newly diagnosed or recurrent HGG.
Further studies should be pursued to define more clearly the therapeutic role of SRS.
Abbreviations: AA = anaplastic astrocytoma, AOA = anaplastic oligoastrocytoma, BVZ = bevacizumab, CNS = central nervous
system, EBRT = external brain radiation therapy, FSRT = fractionated stereotactic radiation therapy, GBM = glioblastoma, HGG =
high-grade gliomas, HRs = hazard ratios, HSRT = hypofractionated stereotactic radiation therapy, IDH = isocitrate dehydrogenase,
KPS = Karnofsky Performance Scale, MGMT =O6-methylguanine- DNAmethyltransferase, OA = anaplastic oligodendroglioma, OS
= overall survival, PFS = progression-free survival, RN = radiation necrosis, RT = radiation therapy, RTOG/EORTC = Radiation
Therapy Oncology Group/European Organization for Research and Treatment of Cancer, SFRS = single fraction radiosurgery, SRS
= stereotactic radiosurgery, TMZ = temozolomide, TTF = tumor treating fields.
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11. Introduction
The heterogeneous category of high-grade gliomas (HGGs)
consists of glioblastoma multiforme (GBM), anaplastic astrocy-
tomas (AAs), anaplastic oligodendrogliomas (AO), and the rare
anaplastic oligoastrocytomas (AOAs). Almost 80% of primary
central nervous system (CNS) gliomas consist of GBM and AA.[1]
In the classification system by the World Health Organization,
the molecular genotype is now a central component of
subclassifying these tumors.[2,3] The standard treatment of newly
diagnosed HGG is maximal safe resection followed by radiation
therapy (RT) with concomitant and adjuvant chemotherapy.[4,5]
Local RT following surgery was found to prolong median
survival in GBM from 3 months without any treatments or 6
months with surgery alone to 12 months with both surgery and
RT [4,6]; furthermore, surgical resection with postoperative RT
has yielded an approximate median survival time of 36 months
for patients with AA.[1] The addition of tumor treating fields
(TTFs) appears to prolong this further.[7] Tumor recurrence
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recurrences within 2cm of the original lesion.[2,8,9]
Recurrence typically occurs within about 8 months after
primary treatment.[10] A universally agreed upon treatment
protocol has yet to be clearly established for recurrent HGG, but
without treatment, survival is limited with a 3 to 6-month median
survival without treatment.[11] Treatment of recurrence varies
but can include reresection, systemic therapy, reirradiation, and
TTF.[8,12] Although there is growing support for reresection of
recurrent gliomas, surgery alone has been shown to be insufficient
for disease control due to the infiltrative nature of the
disease.[2,13] Reirradiation is a treatment modality that is being
actively investigated. The primary concern from a toxicity
perspective is the concern for cumulative radiation injury and the
potential for radiation necrosis (RN).[8] However, reassuring
evidence from recent primate studies, initial clinical series, and
prospective trials appear to show considerable recovery of vital
CNS structures after radiation.[8] As 90% of recurrence occurs
within 2cm of the edge of the primary tumor[14] and metastatic
disease is rare, delivery of high-dose localized radiation—called
stereotactic radiosurgery (SRS)—could theoretically improve
local tumor control, introducing a tolerable increase in
complications.[14,15]
Radiation exposure leads to both parenchymal and vascular
damage, causing cell death to tumor cells along with healthy
oligodendrocytes, neural progenitors, and endothelial cells;
microglia and macrophages, on the contrary, tend to be more
resistant to irradiation and ultimately induce an inflammatory
response.[16] Song et al[17] observed the effects of SRS on mice
tumor cells that initially contributed to vascular occlusion leading
to hypoxia and cell death in addition to directly killing tumor cells
by DNA double-strand breaks; strong antitumor immunity may
also later be stimulated as a result of tumor antigens released from
dying or dead tumor cells. SRS using cobalt source was first used
for intracranial pathology in 1987,[18] and since then, this field
has seen tremendous growth and advancement in terms of the
kind of pathologies treated, dose planning, and radiation safety
profiles.
SRS can be given as a single fraction radiosurgery (SFRS; single
fraction of a higher radiation dose), fractionated stereotactic RT
(FSRT; 2–5 fractions of a lower radiation dose), or hypofractio-
nated stereotactic RT (HSRT; greater than 5 fractions of a higher
radiation dose)—all of which improve accuracy of dose delivery
with rapid reduction of dosage within critical areas.[8,19] SFRS is
typically used for small tumors located in noneloquent areas, as
symptomatic RN is a concern for larger tumors.[8,20] FSRT, on
the contrary, has fewer severe side effects and can be used to treat
larger tumors that may be located in critical areas [8,20]; however,
RN is still a possible side effect.[2] HSRT allows for reduced
treatment time, decreases patient discomfort, and can treat larger
tumors with a smaller risk of acute toxicity in addition to reduced
occurrences of symptomatic RN.[8]
There is still debate in the literature in regards to whether FSRT
or SFRS is more effective with differing reports from in vitro
studies.[21] However, preclinical data and clinical experience
seem to support using multiple fractions over several days instead
of a single large fraction.[19,22] Nahum[19] explained that the
optimal fraction size and number is dependent on certain
mathematical models related to the therapeutic ratio of tumor
and critical tissues; the therapeutic ratio can then help guide
appropriate fractionation plans for different patients. Nahum[19]
also noted that SRS is rarely used alone, which can decrease the
predicative value of the therapeutic ratio when considering the2unknown combined effects of various multimodal treatment
plans that can influence tumor killing and incidence of
complications; regardless, there is still strong theoretical support
for treatment to move toward larger fraction sizes.[19]
Acute toxicity from SRS treatment includes fatigue, alopecia at
the entry/exit field, and radiation dermatitis.[10] Many of the side
effects of localized high-dose RT have been shown to be mild,
infrequent, and resolvable with symptomatic treatment with the
exception of RN, which can be severe and permanent.[2] Overall,
neurotoxicity from SRS has been found to be dose dependent[15]
and has an estimated risk of 3% for RN based on dose–curves[10]
with a reported range between 0% and 31%.[15] However,
neurotoxicity directly attributed to reirradiation is difficult to
determine, as most patients receive aggressive multimodal
treatment including surgery, steroids, radiation, and systemic
therapy, which may act as confounding factors.[10]
SRS combined with systemic therapy, such as bevacizumab
(BVZ), has been shown to potentially improve median progres-
sion-free survival (PFS).[10] Concurrent chemotherapy is thought
to have a radiosensitizing effect or other synergistic quali-
ties.[10,15] Omuro et al[23] found that the addition of BVZ to the
treatment plan led to fewer adverse side effect symptoms; this was
attributed to the properties of BVZ, which cause decreased
vascular permeability and, in turn, decreased peritumoral edema.
Einstein et al[24] reported that concurrent temozolomide (TMZ)
with SRS significantly prolonged median survival compared with
SRS alone (20.8 vs 11 months, P= .037). Another study showed
that chemotherapy with SRS was associated with increased
median OS compared with SRS alone (34.5 vs 10.9 months,
P= .013); median OS was also significantly increased with
external brain RT (EBRT) and SRS compared with EBRT alone
(25 vs 13 months, P= .0335).[25]
There are several studies reporting the use of SRS for recurrent
HGG and newly diagnosed HGG. Efficacy results have been
conflicting with some studies suggesting benefit and others
detriment.
2. Methods
2.1. Literature review
Literature searches were performed on April 6, 2016, via PubMed
for publications from 1992 to 2016. Only human studies and
English-language publications were included. Key phrases used in
the searches were “stereotactic radiosurgery for high grade
gliomas” with 145 search results, “gamma knife surgery for high
grade gliomas”with 122 search results, “stereotactic radiosurgery
for recurrent gliomas’ with 222 search results, ‘stereotactic
radiosurgery for primary gliomas” with 171 results, “stereotactic
radiosurgery for newly diagnosed gliomas”with 43 search results,
and “stereotactic radiosurgery for glioblastoma” with 291 search
results. In addition, a small number of articles that were found as
references listed in other articles thatwere obtained from the above
PubMed searches were included.[23,26–28]
Ethical board approval was not necessary, as the study is a
meta-analysis of already published literature. Only retrospective
observational studies, prospective observational studies, and
randomized clinical trials were included in this literature analysis;
case reports, case series, and reviews were excluded. Studies that
used SRS specifically for the treatment of HGG—classified as
World Health Organization grade III and IV gliomas—were
included, while the use of SRS for treatment of other disease
entities was excluded. In addition, only studies that measured
median OS from time of initial diagnosis were included in this
Table 1
Inclusion and exclusion criteria of studies using stereotactic
radiosurgery for high-grade gliomas.
Inclusion criteria
Procedure
SRS for newly diagnosed or progressive/recurrent HGG
Study size
≥12 subjects
Study Type
Retrospective analysis
Prospective analysis
Randomized controlled clinical trial
Study population
≥5 years old
Other
Reported median overall survival from time of initial diagnosis, median progression-
free survival, or radiation necrosis rate
Exclusion criteria
Procedure
SRS other than for treatment of newly diagnosed or progressive/recurrent HGG
Study size
<12 subjects
Study type
Case reports
Case series
Fetcko et al. Medicine (2017) 96:43 www.md-journal.commeta-analysis; studies that did not report median OS from time of
initial diagnosis were excluded from analysis. Specific inclusion
and exclusion criteria are listed in Table 1.
RN was not specifically defined in all studies that reported
this adverse effect, but the majority of studies declared RN for
patients with representative clinical symptomatic progres-
sion,[8,20,24,26,27,29–31] radiographic signs of progression,[20,29–36]
and/or histologic confirmation.[14,15,20,23,30–33,35,37–42] Major
neurological complications were defined as any neurological
deficit, including cranial nerve palsy, paralysis, seizures, CNS
hemorrhage, stroke and new or worsening neurological signs
or symptoms, which excluded nausea, vomiting, tinnitus, dizzi-
ness, or any other transient mild symptoms. In studies that
used the Radiation Therapy Oncology Group/European Organi-
zation for Research and Treatment of Cancer (RTOG/EORTC)
Acute and the Late Morbidity Scoring Scheme or the Common
Terminology Criteria for Adverse Events grading scale,
major neurological complications were classified as grades 3
and 4.[14,32,43,44]Reviews
Surveys
Editorials
Study population
<5 years old
Other exclusions
Non-English studies
Nonhuman subjects (i.e., animal studies, in vitro studies, etc.)
Insufficient detail
Study not fully explained with insufficient detail or not clearly defined data/results
If study included both recurrent and newly diagnosed HGG subjects and only
reported combined data and results of both recurrent and newly diagnosed HGG
subjects rather than separate results for recurrent HGG subjects and newly diagnosed
HGG subjects
HGG=high-grade gliomas, SRS= stereotactic radiosurgery.2.2. Statistical analysis
Analyses of efficacy endpoints and toxicity including RN and
other major neurological complications were carried out using
STATA12 (StataCorp LP, College Station, TX). A correction of
0.5 was added to both the number of events and the number of
total cases if the count of event was zero. Heterogeneity between
studies was assessed using x2 and I2 test. The inverse-variance
weighted random-effects model, described by Dersimonian and
Laird, was used to calculate pooled estimate of complication
rates as well as 95% confidence intervals. Publication bias was
assessed graphically using funnel plot (Fig. 1) and statistically
using both Begg rank correlation test and Egger linearFigure 1. Funnel plots of (A) radiation necrosis rates for recurrent high-grade gliomas (HGGs), (B) other major neurological complications rates for recurrent HGG,
(C) radiation necrosis rates for newly diagnosed HGG, and (D) other major neurological complications rates for newly diagnosed HGG.
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Table 2
Assessing the methodological quality of a systematic review.
1. Was the review conducted according to a prespecified protocol? Yes
2. Was the question focused and well formulated? Yes
3. Were the right types of studies eligible for the review? Yes
4. Was the method of identifying all relevant information comprehensive? Yes
Is it likely that relevant studies were missed? No
(b) Was publication bias considered? Yes
5. Was the data abstraction from each study appropriate? Yes
(a) Was the methods used in each primary study appraised? Yes
6. Was the information synthesized and summarized appropriately? Yes
(a) If the results were mathematically combined in meta-analysis, were the methods described in sufficient detail and was it reasonable to do so? Yes
Figure 2. Articles evaluated for inclusion in systematic review. n=number of articles, SRS=stereotactic radio surgery, HGG=high-grade glioma.
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Table 3
Patient characteristics for recurrent or progressive high-grade gliomas.
Ref.
Median age
(Range), y Males N Females N
Median tumor
volume (range)
Median
KPS (range)
RPA
class GBM G3G
Navarria et al[8] GBM: 50 (43–75); G3G: 42 (23–81) 15 10 35cm3 (2.46–116.7cm3) [>70] NP 13 AA: 12
Bokstein et al[15] 56 (24–86) 22 25 2.2 cc (0.2–9.5 cc) 90 (50–100)
≥70=37
<70=10
NP 33 14
Niranjan et al[56] 58 (23–89) NP NP 14cm3 (0.26–84.2cm3) [≥60] NP 297 —
Cho et al[20] 49 (16–75) 37 34 14ml (1–115mL) 70 (40–90) NP 42 AA: 20
AO: 9
Skeie et al[48] 55.3 (27–73) 49 28 17.9mL (<5 to >20mL) Mean: 76
≥70=61
<70=16
III-7
IV-45
V-23
VI-2
77 —
Martinez-Carrillo et al[11] 48.7 (18–78) 43 44 8.7 cc (1–42.6cc) Mean: 83
(60–100)
>80=40
80=47
NP 46 AA: 41
Greenspoon et al[51] 53 (36–75) NP NP 32mm (4–60mm) 80 (60–90) NP 31 —
Cabrera et al[44] 53 (25–66) 12 3 NP 90 (80–100) NP 8 7
Combs et al, “Efficacy . . . ” [38] 54 (18–76)-GBM
39 (21–74)-G3G
NP NP NP ≥80=
37-GBM
39-G3G
NP 59 42
Combs et al, “Stereotactic . . . ” [60] 56 (33–76) 19 13 10mL (1.2–59.2mL) 90–100=14
80=14
70=4
III-3
IV-21
V-8
32 —
Cuneo et al[32] 47 (19–76) 45 18 Total: 4.8cc
SRS alone: 5.6cc
SRS+BVZ: 4.5cc
90 NP 49 14
Elliot et al[33] 60.4 (36.5–70.6) 17 9 2.2 cc (0.27–11.9cc) 90 (70–100) III-8
IV-18
16 AA: 5
AOA: 5
Fogh et al[55] 53 (19–86) NP NP 22mL (0.6–104) mL ≥60 NP 105 42
Gutin et al[46] 56 (30–80) 14 11 34 (2–62)cm3 80 (70–100) NP 20 AA: 4
AO: 1
Hudes et al[61] 52 (26–77) 10 10 12.66 (0.89–47.5)cc 80 (60–100) NP 19 AA: 1
Lederman et al[47] 56 51 37 32.7 (1.5–150)cm3 70 (50–100) NP 88 —
Maranzano et al[36] 55 (27–81) 14 8 NP 90 (70–100) III-6
IV-11
V-5
22 —
McKenzie et al[29] 60 (15–71) 17 18 8.54 (0.4–46.56)cc 80 (50–100) NP 29 4
Minniti et al “Fractionated . . . ” [26] 56 (34–72) 22 14 32.1 (12.3–72.4)cm3 70 (60–100) NP 36 —
Minniti et al “Hypofractionated . . . ” [27] 52 (30–72) 32 22 30.3 (12.3–53.4)cm3 80 (60–100) NP 38 16
Koga et al[34] SRS: 43 (17–64)
Ext SRS: 53 (27–79)
NP NP SRS: 15cm3
(3–47cm3)
Ext SRS: 13cm3
(6–19cm3)
SRS: 90
(40–90)
Ext SRS: 70
(40–90)
NP 18 —
Kong et al[35] 49 (5–75) 69 45 10.6 (0.09–79.6)mL 80 (50–100) NP 65 49
Vordermark et al[41] 50 (11–74) 8 11 15 (4–70)mL 90 (60–90) NP 14 5
Pouratian et al[62] 60.7 (12.9–76.9) NP NP 21.3 (0.3–110)cc 80 (40–100) III-3
IV-8
V-15
26 —
Pinzi et al[30] 51 (18–79) 80 48 SFRS: 11
(0.14–120)cm3
FSRT: 2
(0.63–83)cm3
70–80: 118
>80: 10
I-18
II-20
IV-31
VI-41
VII-18
88 40
Sirin et al[63] 50: 12
>50: 7
13 6 13 (7–19)cc 90–100: 9
80: 8
70: 2
III-2
IV-12
V-5
19 —
Yazici et al[64] 37 (22–69) 18 19 24 (2–81)cc NP NP 37 —
Dodoo et al[65] 51 (17–81) NP NP 5.2
(0.03–38.1)mL
(≥70) I-11
II-6
III-10
IV-7
V-21
35 20
Villavicencio et al[66] 56.4 (36–82) 18 8 7.0 (0.4–48.5)cm3 84 (50–100) 3.9 (3–6) 26 —
AA=anaplastic astrocytoma, AO= anaplastic oligodendroglioma, AOA= anaplastic oligoastrocytoma, BVZ=bevacizumab, Ext SRS= extended field SRS 0.5–1cm beyond periphery of tumor volume, FSRT=
fractionated stereotactic radiotherapy, G3G=grade III glioma, GBM=glioblastoma multiforme, KPS=Karnofsky Performance Scale, NP=not published, RPA= recursive partitioning analysis, SRS= stereotactic
radiosurgery, SFRS= single fraction radiosurgery.
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Table 4
Patient characteristics for newly diagnosed high-grade gliomas.
Author
Median age
(Range), y Males N Females N
Median tumor
volume (range)
Median
KPS (range)
RPA
Class G4G G3G
Souhami et al[14] Mean: 56.4 (18–79) 56 33 Mean: 3.0cm3 (0.7–6.0 cm3) 90
(60–100)
III-19
IV-50
V-17
VI-3
GBM: 89 –-
Loeffler et al[39] 51 (14–84) 20 17 4.8cm3 (1.2–72cm3) 85 (70–100) — GBM: 23 AA: 14
Sarkaria et al[31] ≥50=62
<50=53
Male/Female ratio=1.7 18.4cm3
(2.3–59.7cm3)
90–100=60
70–80=42
<70=13
I-16
II-1
III-24
IV-35
V-40
VI-3
GBM: 96 19
Prisco et al[1] 51 (21–78) NP NP 15cc (2.9–70.3cc) 80–100=7
50–70=8
III-1
IV-8
V-6
GBM: 14 1
Omuro et al[23] 55 (17–75) 26 14 (60cc) 90 (70–100) — GBM: 40 —
Einstein et al[24] 62 (21–84) 17 18 (40mm3) 90 (60–100) III-4
IV-13
V-16
VI-2
GBM: 35 —
Gannett et al[53] 54 (5–74) 22 8 24cc (2.1–115.5cc) 90 (50–100) — GBM: 17
GS: 2
AA: 10
AOA: 1
Masciopinto et al[6] 57.7 (20.4–78.6) 22 9 16.4 (2.3–59.7) cm3 80 (20–100) — GBM: 31 —
Mehta et al[40] 57 (20–78) 22 9 17.4 (2.3–59.7)cm3 70 (20–90) IV-14
V-11
VI-6
GBM: 31 —
Nwokedi et al[25] 50.4 (6–85)
EBRT alone: 50=18
>50=15
EBRT+SRS: 50=10
>50=21
NP NP EBRT alone: 29cm3
EBRT+SRS: 25cm3
80 (<70–100)
EBRT alone: <70=13
>70=20
EBRT+SRS: <70=12
>70=19
— 64 —
Shrieve et al[67] 51 (12–84) 45 33 9.4 (0.86–72)cm3 90 (50–100) III-27
IV-29
V-22
GBM: 78 —
Balducci et al[43] 52 (25–72) 26 15 (80mm diameter) (>70) I-5
III-9
IV-26
V-1
GBM: 36 AA: 5
Cardinale et al[37] 43 (20–73) 9 3 15.9 (8–35)cm3 90 (70–100) — GBM: 9 AA: 3
Pouratian et al[62] 58.6 (36.5–70.7) NP NP 13.4 (4.4–56)cc 80 (50–100) III-4
IV-10
V-8
GBM: 22 —
Villavicencio et al[66] 61.3 (27–81) 13 7 5.8 (0.7–47.3)cm3 82 (60–100) 4.5 (3–6) 20 —
Yoshikawa et al[42] GBM: 61.6 (48–78)
AA: 46.1 (28–71)
13 12 19.1 (0.3–90.2) mL GBM: 68.9
(30–90)
AA: 85.7
(70–90)
— 18 7
AA=anaplastic astrocytoma, AOA= anaplastic oligoastrocytoma, EBRT= external brain radiation therapy, G3G=grade III glioma, G4G=grade IV glioma, GBM=glioblastoma multiforme, GS=gliosarcoma,
KPS=Karnofsky Performance Scale, RPA= recursive partitioning analysis, SRS= stereotactic radiosurgery.
Fetcko et al. Medicine (2017) 96:43 Medicineregression test. The pooled estimates of median PFS and median
OS were calculated as a weighted estimate of population
medians: mp ¼
Pk
i¼1
wi
mi
 1
, where mi denotes the median
survival within each study population (i = 1,2, . . . k), wi refers
to the weight of each study and is equivalent to the sample size
of each study divided by the total sample size. This meta-
analysis was compiled according to the Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA)
Checklist, and its quality was assessed using the recommended
checklist from Clinical Epidemiology: Practice and Methods
(Table 2).[45]63. Results
3.1. Literature review
Of the 944 articles found as described in the Methods Section
above, a total of 43 articles were included in this systematic review
based on criteria described in Table 1 (Fig. 2). Twenty-nine studies
with a total of 1686 patients reported the use of SRS for recurrent
HGG,and16studieswitha total of 685patients reported theuseof
SRS for newly diagnosed HGG. This meta-analysis included
mostly retrospective and prospective observational studies with
only 1 randomized clinical trial that investigated the effects of SRS
followed by EBRT and carmustine on median OS in the treatment
Table 5
Overall survival and progression-free survival for recurrent or progressive high-grade gliomas.
Study Type Number of cases
Median PFS from
1st SRS, mo
Median OS from
diagnosis, mo
Navarria et al[8] R HSRT (25) 16 18
Bokstein et al[15] R SRS alone (25)
SRS+TMZ (15)
SRS+BVZ (6)
SRS+carboplatin (1)
5 37.4
Niranjan et al[56] R SRS (297) 4.4 18.1
Cho et al[20] R SFRS (46) vs FSRT (25) NP SFRS: 11
FSRT: 12
Skeie et al[48] R SRS (51) 6 19
Martinez-Carrillo et al[11] R SRS (51) NP All: 21
GBM: 18.9
AA: 39
Greenspoon et al[51] P FSRT (31) 7 9
Cabrera et al[44] P SRS (15) 3.9 14.4
Combs et al, “Efficacy . . . ” [38] P FSRT (101 GBM+G3G) GBM: 5
G3G: 8
GBM: 21
G3G: 50
Combs et al, “Stereotactic . . . ” [60] P SRS (32) 7 22
Cuneo et al[32] R SRS alone (21)
SRS+BVZ (42)
All patients: 6.5
GBM, SRS+BVZ: 8.8
All patients: 41
GBM, SRS+BVZ: 35
Elliot et al[33] R SRS (26) 4.8 25.5
Fogh et al[55] R HSRT+ /- chemotherapy (147) NP GBM: 23
AA: 24
Gutin et al[46] P HSRT+BVZ (25) GBM: 7.3
G3G: 7.5
GBM: 12.5
G3G: 16.5
Hudes et al[61] P HSRT (20) NP 10.5
Lederman et al[47] P SRS+Paclitaxel (88) NP 15
Maranzano et al[36] P SFRS (13) vs FSRT (9) 4 26
McKenzie et al[29] R SRS+chemotherapy (30)
SRS alone (3)
3 22
Minniti et al “Fractionated . . . ” [26] P FSRT+TMZ (36) 5 23.4
Minniti et al “Hypofractionated . . . ” [27] P HSRT+TMZ (54) 6 27.9
Koga et al[34] P SRS (9) or Ext SRS (9) NP SRS: 24
Ext SRS: 21
Kong et al[35] R SRS (114) GBM: 4.6
G3G: 8.6
GBM: 23
G3G: 37.5
Vodermark et al[41] R HSRT (19) 4.9 All: 40.8
GBM: 26
G3G: 57
Pouratian et al[62] R EBRT, then SRS (26) 7.1 17.4
Pinzi et al[30] R SFRS (42) or FSRT (86)
+ /- chemo
+/- resection
11 All: 32
GBM: 25
G3G: 65
Sirin et al[63] R SRS (19) 5.7 21
Yazici et al[64] R SRS (37) 7.9 35.5
Dodoo et al[65] R SRS (55) NP GBM: 24.5
G3G: 49.6
Villavicencio et al[66] R SRS (26) NP 21
BVZ=bevacizumab, EBRT=external beam radiation, Ext SRS= extended field SRS 0.5–1cm beyond periphery of tumor volume, FSRT= fractionated stereotactic radiotherapy, G3G=grade III glioma, GBM=
glioblastoma multiforme, HSRT=hypofractionated stereotactic radiotherapy, MTV=median target volume, OS= overall survival, P=prospective analysis, PFS=progression-free survival, R= retrospective
analysis, SFRS= single fraction radiosurgery, SRS= stereotactic radiosurgery, TMZ= temozolomide.
Fetcko et al. Medicine (2017) 96:43 www.md-journal.comof newly diagnosed HGG. Patient characteristics in studies using
SRS as a treatment for recurrent HGG are listed in Table 3. Patient
characteristics in studies using SRS as a treatment for newly
diagnosed HGG are listed in Table 4.
3.2. Recurrent HGG
For recurrent HGG, the pooled estimates of median PFS (from the
date of first SRS treatment) and median OS (from the day of
diagnosis) were 5.42 and 20.19months, respectively, based on the
identified studies in Table 5. Of the 29 studies of SRS for recurrent7HGG, 21 studies reportedRN (Table 6)with a tally of 87 cases.Of
the studies with specifically stated follow-up times, the duration of
follow-up ranged from 0.5 to 141 months.[11,30] The pooled RN
rate was 5.9% [3.7%, 8.1%] (Test for heterogeneity: x2=89.04,
df=20, P< .001; I2=77.5% and test for publication bias: Egger
test: P< .001; Begg test: P< .001) (Figs. 3 and 1A ). Nineteen
studies reportedmajor neurological complications associatedwith
SRS for recurrent HGG (Table 7), accounting for a total of 88
cases, out of total 1275 cases treated. The pooled estimate of other
major neurological complications rate was 3.3% [1.5%, 5.1%]
(Test for heterogeneity: x2=99.46, df=18, P< .001; I2=81.9%
Table 6
Radiation necrosis for recurrent or progressive high-grade gliomas.
Study Type Number of cases
Number of cases with
radiation necrosis
Radiation
necrosis rate (%)
Navarria et al[8] R HSRT (25) 0 0
Bokstein et al[15] R SRS alone (25)
SRS+TMZ (15)
SRS+BVZ (6)
SRS+carboplatin (1)
3 6.4
Cho et al[20] R SFRS (46) vs FSRT (25) Total: 15
SFRS: 14
FSRT: 1
Total: 21.1
SFRS: 30.4
FSRT: 4.0
Martinez-Carrillo et al[11] R SRS (51) 0 0
Greenspoon et al[51] P FSRT (31) 4 9.8
Combs et al, “Efficacy . . . ” [38] P FSRT (GBM+G3G:101) 1 1.0
Combs et al, “Stereotactic . . . ” [60] P SRS (32) 0 0
Cuneo et al[32] R SRS alone (21)
SRS+BVZ (42)
All patients: 6
SRS alone: 4
SRS+BVZ: 2
Total: 9.5
SRS alone: 6.3
SRS+BVZ: 3.2
Elliot et al[33] R SRS (26) 2 7.7
Fogh et al[55] R HSRT+/- chemotherapy (147) 0 0
Gutin et al[46] P HSRT+BVZ (25) 0 0
Maranzano et al[36] P SFRS (13) vs FSRT (9) 3 13.6
McKenzie et al[29] R SRS+chemotherapy (30)
SRS alone (3)
9 27.3
Minniti et al “Fractionated . . . ” [26] P FSRT+TMZ (36) 3 8.3
Minniti et al “Hypofractionated . . . ” [27] P HSRT+TMZ (54) 4 7.4
Koga et al[34] P SRS (9) or Ext SRS (9) All: 6
SRS: 2
Ext SRS: 4
All: 33:3
SRS: 22.2
Ext SRS: 44.4
Kong et al[35] R SRS (114) 22 19.3
Vodermark et al[41] R HSRT (19) 1 5.3
Pouratian et al[62] R EBRT, then SRS (26) 0 0
Pinzi et al[30] R SFRS (42) or FSRT (86)
+ /- chemo
+ /- resection
7 5.9
Yazici et al[64] R SRS (37) 1 2.7
BVZ=bevacizumab, EBRT=external beam radiation, Ext SRS= extended field SRS 0.5–1cm beyond periphery of tumor volume, FSRT= fractionated stereotactic radiotherapy, G3G=grade III glioma, GBM=
glioblastoma multiforme, HSRT=hypofractionated stereotactic radiotherapy, P=prospective analysis, R= retrospective analysis, SFRS= single fraction radiosurgery, SRS= stereotactic radiosurgery, TMZ=
temozolomide.
Fetcko et al. Medicine (2017) 96:43 Medicineand test for publication bias: Egger test: P= .021; Begg test:
P< .001) (Figs. 4 and 1B). Of the studies that noted specific major
neurological complications, themost commonly reported included
seizures, CNS bleed, and cranial nerve palsy.[46–48]
3.3. Newly diagnosed HGG
For newly diagnosed HGG, the pooled estimates of median PFS
and median OS from 16 studies were 7.89 and 16.87 months,
respectively, based on the identified studies in Table 8. Of
the 16 studies of SRS for newly diagnosed HGG, 12 studies
reported RN (Table 9) with a tally of 47 cases. Of the studies
with specifically stated follow-up times, the duration of follow-
up ranged from 3 to 61 months.[14,40] The pooled RN rate
was 6.5% [3.6%, 9.4%] (Test for heterogeneity: x2=22.02,
df=11, P= .024; I2=50% and test for publication bias: Egger
test: P= .01; Begg test: P= .02) (Figs. 5 and 1C). Nine (2.7%)
studies reported major neurological complications associated
with SRS for newly diagnosed HGG (Table 10), accounting
for a total of 12 cases, out of total 451 cases treated. The
pooled estimate of other major neurological complications
rate not associated with SRS was 1.5% [0.4%, 2.6%] (Test
for heterogeneity: x2=7.95, df=8, P= .44; I2=0.0% and test8for publication bias: Egger test: P= .001; Begg test: P= .009)
(Figs. 6 and 1D). Of the studies that noted specific
major neurological complications, the most commonly
reported included seizures, CNS bleed, stroke, and hemi-
paresis.[23,31,37]
4. Discussion
HGG remains one of the most aggressive cancers that is almost
universally fatal even with intense multimodal therapies,
including surgery, radiation, and systemic therapy.[49] Various
available novel treatments—SRS, brachytherapy, immunothera-
py, TTF, and viral therapy—have both strengths and weaknesses
along with certain side effects.[6] As this disease is characterized
by aggressive local invasion but not distant metastasis, local
delivery of radiation in the form of SRS has been and continues to
be attempted as a treatment strategy in combination with other
treatment modalities with variable reported success rates.4.1. SRS efficacy
For newly diagnosed HGG, the survival is quite poor with a
majority of patients not surviving beyond 24months.[50] GBM in
NOTE: Weights are from random effects analysis
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Figure 3. Forest plot of radiation necrosis rates for recurrent high-grade gliomas (HHGs).
Fetcko et al. Medicine (2017) 96:43 www.md-journal.comparticular has a median survival of 12 to 18 months and only a
10% 5-year survival with maximal treatment.[8,51] Cairncross
et al[52] found increased survival in patients with AO or AOA
who had codeletions of 1p and 19q with the longest
median overall survival (OS) of 14.7 years reported for
those who were treated with procarbazine, lomustine, and
vincristine in addition to EBRT. Our meta-analysis resulted
in an estimate of 7.89 months for median PFS and 16.87 months
for median OS in patients with newly diagnosed HGG.
Several studies utilized a multimodal approach in the treatment
of newly diagnosed HGG that likely contributed to longer
survival times.
Notably, the only randomized trial (RTOG9305) included in
this meta-analysis found no benefit in the treatment of newly
diagnosed HGG with SRS followed by EBRT and carmustine
with a median OS of 13.5 months in the SRS group and 13.6
months in the control group.[14] Souhami et al[14] explained that
SRS provided no benefit evenwhen subgroup analyses were done,
questioning the efficacy of SRS on focal tumor control further
when biopsies and MRI analyses found significant microscopic
tumor extension outside of the contrast-enhancing tumor
regions; they also acknowledged the importance of the temporal
sequence of SRS in regards to outcome as other earlier reports of9SRS in treatment of newly diagnosed HGG occurred after
completion of EBRT rather than before.
Without any treatment, patients with recurrent HGG have a
median survival of about 3 to 6 months.[11,33] More specifically,
GBMpatients typically do not survive beyond 13months even with
temozolomide therapy.[34] For recurrentHGGtreatedwith SRS, this
meta-analysis resulted in an estimate of 5.42months formedian PFS
and 20.19 months for median OS. SRS may be most beneficial for
GBM, particularly with slightly increased treatment margins. Kong
et al[35] found that SRS significantly increased survival compared
with a historic control group for patients with recurrent glioblasto-
mas (23 vs 12 months, P< .001); however, this was not true for
patientswith grade III gliomas treatedwith SRS comparedwith their
historic control counterparts (37.5 vs 26 months, P= .789). Koga
et al[34] found that extended field SRS (0.5–1cm beyond tumor
volume margins) was more effective at local tumor control; yet,
median OS was not statistically significant.
SRS treatment for newly diagnosed HGG appeared most
beneficial for patients younger than 55 years with a Karnofsky
Performance Scale (KPS) score of >70 and those with grade III
gliomas comparedwith grade IV gliomas.[6,24,53] This was similar
for patients with recurrent HGG treated with SRS with favorable
prognostic factors, including younger age, higher KPS score, and
Table 7
Other major neurological complications for recurrent or progressive high-grade gliomas.
Study Type Number of cases
Number of cases with
major neurological complications
Major neurological
complication rate (%)
Navarria et al[8] R HSRT (25) 0 0
Bokstein et al[15] R SRS alone (25)
SRS+TMZ (15)
SRS+BVZ (6)
SRS+carboplatin (1)
0 0
Niranjan et al[56] R SRS (297) “new neurological signs or symptoms”: 69 23.2
Cho et al[20] R SFRS (46) vs FSRT (25) Cranial nerve 2 and 3 palsy: 1 (FSRT) 1.4
Skeie et al[48] R SRS (51) 0 0
Martinez-Carrillo et al[11] R SRS (51) 0 0
Cabrera et al[44] P SRS (15) 1 6.7
Combs et al, “Efficacy . . . ” [38] P FSRT (172 total, 101 GBM+G3G) 0 0
Combs et al, “Stereotactic . . . ” [60] P SRS (32) 0 0
Cuneo et al[32] R SRS alone (21)
SRS+BVZ (42)
Total: 8
Grade 3: 7
(-BVZ: 3,+BVZ: 4)
Grade 4: 1
(-BVZ: 1,+BVZ: 0)
Total: 12.7
Elliot et al[33] R SRS (26) Worsening hemiparesis: 1 3.8
Fogh et al[55] R HSRT+ /- chemotherapy (147) 0 0
Gutin et al[46] P HSRT+BVZ (25) CNS bleed: 1 4.0
Hudes et al[61] P HSRT (20) 0 0
Lederman et al[47] P SRS+Paclitaxel (88) Seizures: 5 5.7
Maranzano et al[36] P SFRS (13) vs FSRT (9) 0 0
McKenzie et al[29] R SRS+chemotherapy (30)
SRS alone (3)
Worsening neurologic function: 2 6.1
Minniti et al “Fractionated . . . ” [26] P FSRT+TMZ (36) 0 0
Minniti et al “Hypofractionated . . . ” [27] P HSRT+TMZ (54) 0 0
R= retrospective analysis, P=prospective analysis, GBM=glioblastoma multiforme, BVZ=bevacizumab, EBRT= external beam radiation, FSRT= fractionated stereotactic radiotherapy, G3G=grade III glioma,
HSRT=hypofractionated stereotactic radiotherapy, SFRS= single fraction radiosurgery, SRS= stereotactic radiosurgery, TMZ= temozolomide.
Fetcko et al. Medicine (2017) 96:43 Medicinesmaller tumor size, and those with grade III gliomas compared
with grade IV gliomas.[2,15,33–35,54,55]
According to the results of our meta-analysis with special
consideration of the results from the 1 randomized clinical trial,
SRS seemed to show a slight efficacy at treating recurrent HGG
(pooled OS 20.19 months) compared with newly diagnosed
HGG (pooled OS 16.87 months); therefore, SRS may reasonably
be considered as part of treatment for recurrent HGG considering
the limited treatment options for HGG, the positive safety profile
of SRS, and the relatively favorable quality of life associated with
SRS. However, SRS did not seem to show a benefit in treatment of
newly diagnosed HGG.
The primary limitation of this meta-analysis was the selection
bias present in all of the articles analyzed. This arose from the lack
of randomized prospective clinical trials. This meta-analysis
contained mostly retrospective and prospective observational
studies with only 1 randomized clinical trial. Selection bias was
noted in some studies as more favorable results for SRS in the
treatment of HGG for patients with smaller tumor size, higher
performance status, good response to initial chemoradiation
therapy, and a prolonged time interval to recurrence [49]; therefore,
these patients are not representative of the general population of
patients with HGG, as they may presumably have different and
perhaps better outcomes. When analyzing case selections of
patients treatedwith external beamRT,multiple studies found that
SRS-eligible patients had significantly prolonged median OS
compared with SRS-ineligible patients.[14,56]
One of the biggest limitations of the current study is that the
current literature on SRS treatment for HGG offers limited10interpretation due to small sample sizes in studies, ranging from
15 to 147 patients, and the use of various treatment modalities,
which differed both between studies and among patients within
the individual studies. The robustness of ameta-analysis is strictly
dependent on the quality of studies included in the meta-analysis.
There were also limitations associated with the heterogeneous
patient population that exhibited a median OS in patients with
recurrent tumors ranging from 9 months in GBM patients[51] to
57 months in grade III glioma patients[41] and a median OS in
patients with primary tumors ranging from 9.5 months in GBM
patients[6] to 33 months in AA patients.[37] Not only were all
types of HGGs grouped together, but also other influencing
factors, such as isocitrate dehydrogenase (IDH) status and O6-
methylguanine-DNA methyltransferase (MGMT) status, were
not analyzed in this meta-analysis making the effects of SRS on
OS and PFS not entirely clear at this time.[57] In addition, there is
publication bias present in the body of literature available
assessing the role of SRS in treatment of HGG. We evaluated the
publication bias using best available statistical tools (Egger and
Begg test); however, as these methods are based on strong and
unverifiable assumptions, they do not guarantee the validity of
conclusions.[58]
This meta-analysis was also statistically limited in its ability to
provide more accurate results and interpretation of the current
data.Many of the studies included in this analysis did not provide
necessary values, such as hazard ratios (HRs), ranges, and
confidence intervals, that would have facilitated in a more
thorough statistical evaluation of median PFS and median OS.
Median survival times or survival rates at a particular point in
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Figure 4. Forrest plot of other major neurological complications rates for recurrent high-grade gliomas (HHGs).
Fetcko et al. Medicine (2017) 96:43 www.md-journal.comtime are not reasonable surrogate measures for meta-analyses of
survival outcomes and that, wherever possible, HRs should be
calculated. Individual publications reporting on time to event
outcomes, therefore, should provide more detailed statistical
information, preferably log HRs and their variances, or their
estimators.[59] Future clinical studies should strive to include
these data in their published literature to aid in improved meta-
analysis related to survival data in cancer trials.4.2. SRS toxicity
Primary complications of concern associated with SRS are RN
and othermajor neurological deficits. For the studies reporting on
newly diagnosed HGG, our meta-analysis resulted in a pooled
RN rate of 6.5% and a pooled estimate of other major
neurological complications rate of 1.5%. Although documented
neurotoxicity rates are low, the short life expectancy of patients
with HGG makes calculating the true long-term toxicity risk of
SRS challenging. However, the current data suggest that SRS is a
safe treatment for newly diagnosed HGGwith a small risk of RN
and even smaller risk of major neurological complications. In
general, according to the results of this systematic review,
although SRS is safe with a very low risk of major neurological11complication, SRS does not seem to provide improvement in OS
for patients with newly diagnosed HGG.
For the studies reporting on recurrent HGG, this meta-analysis
resulted in a pooled RN rate of 5.9% and a pooled estimate of
other major neurological complications rate of 3.3%. Reporting
the true toxicity risk of SRS is difficult even though documented
toxicity is low because of the short life expectancy of patients
with HGG. Overall, the current data suggest that SRS is a safe
treatment option with a small risk of RN or any other major
neurological complications; however, its efficacy in treating
recurrent HGG still needs to be validated by large prospectively
randomized clinical trials.
The variable definition of RN limited this study in addition to
variable duration of follow-up times with short follow-up times
likely resulting in lower reported toxicity rates than studies with
longer follow-up times. Furthermore, the likelihood of detecting
and reporting on all major neurological complications of every
patient in all the retrospective studies is low.5. Conclusion
The rapidly progressive nature of HGG adds to the difficulty in
creating effective treatment plans that should focus on short
Table 8
Overall survival and progression free survival for newly diagnosed high-grade gliomas.
Study Type Number of cases Median PFS from 1st SRS, mo) Median OS from diagnosis, mo
Souhami et al[14] RCT SRS+EBRT+BCNU (89) NP 13.5
Loeffler et al[39] P SRS (37) NP 26
Sarkaria et al[31] R SRS+EBRT (115) NP 24
Prisco et al[1] R EBRT+SRS (15) NP 21.4
Omuro et al[23] P HSRT+TMZ+BVZ (40) 10 19
Einstein et al[24] P SRS (19)
SRS+TMZ (16)
NP All: 15.8
SRS: 11
SRS+TMZ: 20.8
Gannett et al[53] P EBRT+SRS (16)
EBRT+SRS+carboplatin, BCNU, or PCV (14)
7 All: 13.9
Masciopinto et al[6] P SRS (31) 7 9.5
Mehta et al[40] P SRS+EBRT (29)
SRS (2)
5.5 10.5
Nwokedi et al[25] R EBRT alone (33)
EBRT+SRS (31)
NP All: 16
EBRT alone: 13
EBRT+SRS: 25
Shrieve et al[67] R SRS (78) NP All:19.9
Balducci et al[43] P EBRT+FSRT+TMZ (41) All: 11
GBM: 10
All: 30
GBM: 28
Cardinale et al[37] P SRS+EBRT (12) NP GBM: 16
AA: 33
Pouratian et al[62] R EBRT, then SRS (22) 8.3 15.1
Villavicencio et al[66] R SRS (20) NP 11.5
Yoshikawa et al[42] R SRS (25) NP 20.7
BCNU= carmustine, BVZ=bevacizumab, EBRT=external beam radiation therapy, FSRT= fractionated stereotactic radiotherapy, G3G=grade III glioma, GBM=glioblastoma multiforme, HSRT=
hypofractionated stereotactic radiotherapy, NP=not published, P=prospective analysis, PCV= combination procarbazine, lomustine, and vincristine, PFS=progression-free survival, OS= overall survival, R=
retrospective analysis, RCT= randomized clinical trial, SFRS= single fraction radiosurgery, SRS= stereotactic radiosurgery, TMZ= temozolomide.
Fetcko et al. Medicine (2017) 96:43 Medicineduration therapy, few side effects, and limited hospitalizations in
attempts to balance aggressive therapies and maintain a good
quality of life.[6] SRS is a short treatment option that does not
sacrifice large amounts of time precious to these patients who
already have a limited life expectancy. This meta-analysis
suggests that SRS may hold potential as a treatment option for
recurrent HGG, especially with its low complication profile with
a 5.9% rate of RN and a 3.3% rate of other major neurologicalTable 9
Radiation necrosis for newly diagnosed high-grade gliomas.
Study Type Number of cases
Souhami et al[14] RCT SRS+EBRT+BCNU (89)
Loeffler et al[39] P SRS (37)
Sarkaria et al[31] R SRS+EBRT (115)
Omuro et al[23] P HSRT+TMZ+BVZ (40)
Einstein et al[24] P SRS (19)
SRS+TMZ (16)
Gannett et al[53] P EBRT+SRS (16)
EBRT+SRS+carboplatin, BCNU,
Mehta et al[40] P SRS+EBRT (29)
SRS (2)
Nwokedi et al[25] R EBRT alone (33)
EBRT+SRS (31)
Balducci et al[43] P EBRT+FSRT+TMZ (41)
Cardinale et al[37] P SRS+EBRT (12)
Pouratian et al[62] R EBRT, then SRS (22)
Yoshikawa et al[42] R SRS (25)
BCNU= carmustine, BVZ=bevacizumab, EBRT=external beam radiation therapy, FSRT= fractionat
hypofractionated stereotactic radiotherapy, P=prospective analysis, PCV=combination procarbazine, lo
retrospective analysis, RCT= randomized clinical trial, TMZ= temozolomide.
12complications. However, the data do not show strong enough
evidence for SRS as treatment of HGG to be considered part of
the standard care.
RN and other major neurological complications remain
primary concerns with the use of SRS for treating HGG;
however, the rates of both RN and other major neurological
complications were found to be quite low for recurrent and newly
diagnosed HGG treated with SRS in this meta-analysis. TheNumber of cases with
radiation necrosis
Radiation
necrosis rate (%)
7 7.9
5 13.5
17 14.8
2 5
3 8.6
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0 0
4 12.9
EBRT+SRS: 2 6.5
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ed stereotactic radiotherapy, G3G=grade III glioma, GBM=glioblastoma multiforme, HSRT=
mustine, and vincristine, SFRS= single fraction radiosurgery, SRS= stereotactic radiosurgery, R=
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Figure 5. Forest plot of radiation necrosis rates for newly diagnosed high-grade gliomas (HHGs).
Fetcko et al. Medicine (2017) 96:43 www.md-journal.comresults of this systematic review support that SRS is a rather safe
treatment option; however, its efficacy still needs to be
demonstrated by large prospective randomized controlled clinical
trials. Further studies should be pursued to help define moreTable 10
Other major neurological complications for newly diagnosed high-gr
Ref. Type Number of cases
Souhami et al[14] RCT SRS+EBRT+BCNU (89)
Sarkaria et al[31] R SRS+EBRT (115)
Omuro et al[23] P HSRT+TMZ+BVZ (40)
Einstein et al[24] P SRS (19)
SRS+TMZ (16)
Gannett et al[53] P EBRT+SRS (16)
EBRT+SRS+carboplatin, BCNU, or PC
Nwokedi et al[25] R EBRT alone (33)
EBRT+SRS (31)
Balducci et al[43] P EBRT+FSRT+TMZ (41)
Cardinale et al[37] P SRS+EBRT (12)
Yoshikawa et al[42] R SRS (25)
BCNU= carmustine, BVZ=bevacizumab, EBRT= external beam radiation therapy, GBM=glioblastom
combination procarbazine, lomustine, and vincristine, R= retrospective analysis, RCT= randomized clini
13clearly the therapeutic role that SRS plays in the treatment of
HGG. With more than 40,000 people worldwide who have
undergone SRS for recurrent HGG, this treatment modality is in
need of additional research to determine its value in treating bothade gliomas.
Number of cases with major
neurological complications
Major neurological
complication rate (%)
Grade 3: 3 Grade 3: 3.8
Hemiparesis: 1 0.87
Total: 3
Ischemic stroke: 1
CNS bleed: 2
Total: 7.5
Stroke: 1 2.9
V (14)
0 0
0 0
Grade 3: 1 Grade 3: 2.4
Total: 3
Neurologic progression: 1
Seizure: 2
Total: 25
0 0
a multiforme, HSRT=hypofractionated stereotactic radiotherapy, P=prospective analysis, PCV=
cal trial, SRS= stereotactic radiosurgery, TMZ= temozolomide.
[10] Taunk NK, Moraes FY, Escorcia FE, et al. External beam re-irradiation,
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.438)
Gannett et al
Yoshikawa et al
Nwokedi et al
Einstein et al
Balducci et al
Souhami et al
Omuro et al
Sarkaria et al
Cardinale et al
Study
ID
0.01 (0.00, 0.03)
0.02 (-0.03, 0.06)
0.02 (-0.03, 0.07)
0.01 (-0.01, 0.03)
0.03 (-0.03, 0.08)
0.02 (-0.02, 0.07)
0.03 (-0.00, 0.07)
0.08 (-0.01, 0.16)
0.01 (-0.01, 0.03)
0.25 (0.01, 0.49)
ES (95% CI)
100.00
6.04
4.24
26.79
4.03
5.50
8.73
1.84
42.62
0.20
%
Weight
0 .1 .2 .3 .4
Figure 6. Forest plot of other major neurological complication rates for newly diagnosed high-grade gliomas (HHGs).
Fetcko et al. Medicine (2017) 96:43 Medicinerecurrent and newly diagnosed HGG in order to help guide
clinical practice.[56]
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